Close Menu

NEW YORK – Daiichi Sankyo and AstraZeneca have begun a Phase II clinical trial of datopotamab deruxtecan in non-small cell lung cancer with actionable genomic alterations.

The global, single-arm trial, called TROPION-Lung05, is evaluating the treatment in NSCLC patients with a variety of activating alterations in genes, such as EGFR, ALK, ROS1, NTRK, BRAF, MET, or RET. Participants must have cancer that has progressed despite treatment with a tyrosine kinase inhibitor and platinum-based chemotherapy with or without other systemic therapies.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Apr
27
Sponsored by
Biognosys

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Jun
16
Sponsored by
Biognosys

This webinar, the second in our Next-Generation Proteomics for Precision Oncology series, will discuss how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients.